Analysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutations
Authors:
- Konnie M. HebedaKHKonnie M. Hebeda
- Ludmila BoudováLBLudmila Boudová
- Maarten F. CorstenMCMaarten F. Corsten
- Nikola PtákováNPNikola Ptáková
- Torsten HaferlachTHTorsten Haferlach
- Aniek O. de GraafAGAniek O. de Graaf
- Jaroslav CermakJCJaroslav Cermak
- Tomas VanecekTVTomas Vanecek
- Joop H. JansenJJJoop H. Jansen
- Marian J. P. L. Stevens-KroefMarian J. P. L. Stevens-Kroef
- Leonie I. KroezeLKLeonie I. Kroeze
Open Access
- 9 October 2025
- journal article
- research article
- Published by Springer Nature in Journal of Hematopathology
- Vol. 18 (1) , 1-9
Abstract
We collected 97 cases of myeloid neoplasia with the rare cytogenetic event of isolated trisomy 19 (+19), with the aim to characterize this group clinically and pathologically. 51 patients with myelodysplastic syndrome (MDS +19) and 11 patients with myelodysplastic/myeloproliferative neoplasms (MDS/MPN +19) presented with +19 at disease onset and were further analyzed. Patients with insufficient data were excluded. We collected additional clinical and laboratory data and performed mutation analysis on available bone marrow biopsies. The 62 patients of both disease groups turned out to be remarkably homogeneous in terms of male sex (85%), the presence of anemia with increased numbers of ring sideroblasts (RS, 80%), the absence of an SF3B1 mutation (95%), and the overall rather consistent presence of SRSF2 (61%) or ASXL1 (39%) mutations. MDS +19 patients with available follow-up (1 month to 7.5 years) presented or progressed with significant fibrosis (45%), leuko- or monocytosis (13%) or acute leukemia (28%). Compared to a control cohort of 23 patients with MDS and an SRSF2 mutation, but without isolated +19 (MDS-SRSF2), the 16 MDS +19 patients with SRSF2 mutation and the 12 MDS +19 patients with an ASXL1 mutation showed a striking difference in the presence of ≥ 15% RS (73% and 67% versus 17% in MDS-SRSF2) and the occurrence of fibrosis (44% and 57% versus 4% in MDS-SRSF2). Although all individual features observed in the MDS +19 and MDS/MPN +19 cohorts are seen in MDS and MDS/MPN in general, their combination is rather unique and provides clues regarding disease evolution in this rare, cytogenetically defined group of myeloid neoplasia.Keywords
This publication has 53 references indexed in Scilit:
- Chromosome instability is associated with hypodiploid clones in myelodysplastic syndromesHereditas, 2008
- Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridizationGenes, Chromosomes and Cancer, 2001
- Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patientsLeukemia Research, 2000
- Cytogenetic clonality analysis: typical patterns in myelodysplastic syndrome and acute myeloid leukaemiaBritish Journal of Haematology, 1996
- Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasmsCancer Genetics and Cytogenetics, 1994
- Analysis of karyotype, SCE, and point mutation of RAS oncogene in Indian MDS patientsCancer Genetics and Cytogenetics, 1993
- Cytogenetic studies in 112 cases of untreated myelodysplastic syndromesCancer Genetics and Cytogenetics, 1992
- Trisomy 19 in a patient with myelodysplastic syndrome and thrombocytosisCancer Genetics and Cytogenetics, 1990
- Chromosome study of 85 patients with myelodysplastic syndromeCancer Genetics and Cytogenetics, 1988
- Cytogenetic findings in the dysmyelopoietic syndromeCancer, 1982